Murphy Natalia A, Franklin Robin J M
Wellcome Trust-Medical Research Council Cambridge Stem Cell Institute, Cambridge, United Kingdom; University of Cambridge, Cambridge, United Kingdom.
Wellcome Trust-Medical Research Council Cambridge Stem Cell Institute, Cambridge, United Kingdom; University of Cambridge, Cambridge, United Kingdom.
Prog Brain Res. 2017;231:135-163. doi: 10.1016/bs.pbr.2016.12.013. Epub 2017 Feb 23.
Demyelinating diseases, such as multiple sclerosis (MS), are responsible for a significant portion of the neurological disability burden worldwide, especially in young adults. Demyelination can be followed by a spontaneous regenerative process called remyelination, in which new myelin sheaths are restored to denuded axons. However, in chronic demyelinating disease such as MS, this process becomes progressively less efficient. This chapter reviews the biology of remyelination and the rationale and strategies by which it can be enhanced therapeutically in acquired demyelinating disease.
脱髓鞘疾病,如多发性硬化症(MS),在全球范围内造成了很大一部分神经功能障碍负担,尤其是在年轻人中。脱髓鞘之后可能会出现一个称为髓鞘再生的自发再生过程,在此过程中,新的髓鞘会重新覆盖裸露的轴突。然而,在诸如MS等慢性脱髓鞘疾病中,这个过程的效率会逐渐降低。本章回顾了髓鞘再生的生物学机制,以及在获得性脱髓鞘疾病中通过治疗增强髓鞘再生的基本原理和策略。